Browse by author
Lookup NU author(s): Professor David KavanaghORCiD, Professor Tim Goodship
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Mutations in the genes for three complement regulators-complement factor H (CFH), membrane cofactor protein (MCP), and factor I (IF)-have now been described in patients with atypical HUS. The functional effects of these mutations have been studied in detail and have been shown to affect secretion, expression, and regulatory function. Genotype-phenotype correlations have shown that the majority of patients with CFH, MCP, and FI mutations develop end-stage renal failure. The outcome of transplantation is poor in patients known to have either a CFH or FI mutation, with approximately 80% of patients losing the graft to recurrent disease within 2 years. In contrast, patients known to have only an MCP mutation have a satisfactory transplantation outcome. This is expected because MCP is a transmembrane regulator and allografts will therefore be protected by wild-type MCP. Combined liver/kidney transplantation for patients known to have a CFH mutation has not been successful to date. There is optimism that in the future, targeted complement inhibitors will be of major therapeutic benefit in this condition. Copyright © 2006 by Thieme Medical Publishers, Inc.
Author(s): Kavanagh D, Goodship THJ
Publication type: Article
Publication status: Published
Journal: Seminars in Thrombosis and Hemostasis
Year: 2006
Volume: 32
Issue: 2
Pages: 155-159
ISSN (print): 0094-6176
ISSN (electronic): 1098-9064
Publisher: Thieme Medical Publishers
URL: http://dx.doi.org/10.1055/s-2006-939771
DOI: 10.1055/s-2006-939771
PubMed id: 16575690
Altmetrics provided by Altmetric
